Rare diseases
Investigational molecules
Locations
290 conditions with trials, the busiest first
1 641 trials across Europe, recruiting first
Study of Ritlecitinib (50 mg and 100 mg daily) compared to placebo in adults with nonsegmental vitiligo
BelgiumStudy on the Effects of Upadacitinib in Adults and Adolescents with Non-Segmental Vitiligo Eligible for Systemic Treatment
BelgiumStudy of Oral Ozanimod as Maintenance Treatment for Adults with Moderate to Severe Crohn's Disease
BelgiumStudy on the Effectiveness of Povorcitinib for Adults with Nonsegmental Vitiligo
BulgariaStudy on the Effectiveness and Safety of Rosnilimab for Patients with Moderate to Severe Ulcerative Colitis
AustriaStudy on the Effectiveness of Povorcitinib for Adults with Nonsegmental Vitiligo
BelgiumStudy on Long-Term Safety and Efficacy of Deucravacitinib for Patients with Moderate-to-Severe Plaque Psoriasis
CzechiaStudy on the Effects of Human Normal Immunoglobulin in Adults with Dermatomyositis
BelgiumStudy on Rezpegaldesleukin for Treating Moderate-to-Severe Atopic Dermatitis in Adults
BulgariaStudy on Long-Term Safety of Cendakimab for Adults and Adolescents with Eosinophilic Esophagitis
AustriaStudy of Baricitinib for Children and Adolescents with Moderate-to-Severe Atopic Dermatitis
AustriaStudy on the Effectiveness and Safety of Abatacept Biosimilar (DRL_AB) and Methotrexate for Patients with Moderate to Severe Rheumatoid Arthritis
BulgariaThe therapies tested most often in Immune system disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
